The Market Reports

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Rare Disease Pharmaceutical Service Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Drug Discovery
1.2.3 Clinical Trials
1.2.4 Others
1.3 Market by Application
1.3.1 Global Rare Disease Pharmaceutical Service Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Congenital and Genetic Diseases
1.3.3 Tumors and Cancer
1.3.4 Endocrine Diseases
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Rare Disease Pharmaceutical Service Market Perspective (2019-2030)
2.2 Rare Disease Pharmaceutical Service Growth Trends by Region
2.2.1 Global Rare Disease Pharmaceutical Service Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Rare Disease Pharmaceutical Service Historic Market Size by Region (2019-2024)
2.2.3 Rare Disease Pharmaceutical Service Forecasted Market Size by Region (2025-2030)
2.3 Rare Disease Pharmaceutical Service Market Dynamics
2.3.1 Rare Disease Pharmaceutical Service Industry Trends
2.3.2 Rare Disease Pharmaceutical Service Market Drivers
2.3.3 Rare Disease Pharmaceutical Service Market Challenges
2.3.4 Rare Disease Pharmaceutical Service Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Rare Disease Pharmaceutical Service Players by Revenue
3.1.1 Global Top Rare Disease Pharmaceutical Service Players by Revenue (2019-2024)
3.1.2 Global Rare Disease Pharmaceutical Service Revenue Market Share by Players (2019-2024)
3.2 Global Rare Disease Pharmaceutical Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Rare Disease Pharmaceutical Service Revenue
3.4 Global Rare Disease Pharmaceutical Service Market Concentration Ratio
3.4.1 Global Rare Disease Pharmaceutical Service Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Rare Disease Pharmaceutical Service Revenue in 2023
3.5 Rare Disease Pharmaceutical Service Key Players Head office and Area Served
3.6 Key Players Rare Disease Pharmaceutical Service Product Solution and Service
3.7 Date of Enter into Rare Disease Pharmaceutical Service Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Rare Disease Pharmaceutical Service Breakdown Data by Type
4.1 Global Rare Disease Pharmaceutical Service Historic Market Size by Type (2019-2024)
4.2 Global Rare Disease Pharmaceutical Service Forecasted Market Size by Type (2025-2030)
5 Rare Disease Pharmaceutical Service Breakdown Data by Application
5.1 Global Rare Disease Pharmaceutical Service Historic Market Size by Application (2019-2024)
5.2 Global Rare Disease Pharmaceutical Service Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Rare Disease Pharmaceutical Service Market Size (2019-2030)
6.2 North America Rare Disease Pharmaceutical Service Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Rare Disease Pharmaceutical Service Market Size by Country (2019-2024)
6.4 North America Rare Disease Pharmaceutical Service Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Rare Disease Pharmaceutical Service Market Size (2019-2030)
7.2 Europe Rare Disease Pharmaceutical Service Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Rare Disease Pharmaceutical Service Market Size by Country (2019-2024)
7.4 Europe Rare Disease Pharmaceutical Service Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Rare Disease Pharmaceutical Service Market Size (2019-2030)
8.2 Asia-Pacific Rare Disease Pharmaceutical Service Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Rare Disease Pharmaceutical Service Market Size by Region (2019-2024)
8.4 Asia-Pacific Rare Disease Pharmaceutical Service Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Rare Disease Pharmaceutical Service Market Size (2019-2030)
9.2 Latin America Rare Disease Pharmaceutical Service Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Rare Disease Pharmaceutical Service Market Size by Country (2019-2024)
9.4 Latin America Rare Disease Pharmaceutical Service Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Rare Disease Pharmaceutical Service Market Size (2019-2030)
10.2 Middle East & Africa Rare Disease Pharmaceutical Service Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Country (2019-2024)
10.4 Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ultragenyx
11.1.1 Ultragenyx Company Detail
11.1.2 Ultragenyx Business Overview
11.1.3 Ultragenyx Rare Disease Pharmaceutical Service Introduction
11.1.4 Ultragenyx Revenue in Rare Disease Pharmaceutical Service Business (2019-2024)
11.1.5 Ultragenyx Recent Development
11.2 Chiesi
11.2.1 Chiesi Company Detail
11.2.2 Chiesi Business Overview
11.2.3 Chiesi Rare Disease Pharmaceutical Service Introduction
11.2.4 Chiesi Revenue in Rare Disease Pharmaceutical Service Business (2019-2024)
11.2.5 Chiesi Recent Development
11.3 Sciensus
11.3.1 Sciensus Company Detail
11.3.2 Sciensus Business Overview
11.3.3 Sciensus Rare Disease Pharmaceutical Service Introduction
11.3.4 Sciensus Revenue in Rare Disease Pharmaceutical Service Business (2019-2024)
11.3.5 Sciensus Recent Development
11.4 Abbvie
11.4.1 Abbvie Company Detail
11.4.2 Abbvie Business Overview
11.4.3 Abbvie Rare Disease Pharmaceutical Service Introduction
11.4.4 Abbvie Revenue in Rare Disease Pharmaceutical Service Business (2019-2024)
11.4.5 Abbvie Recent Development
11.5 Orpharma
11.5.1 Orpharma Company Detail
11.5.2 Orpharma Business Overview
11.5.3 Orpharma Rare Disease Pharmaceutical Service Introduction
11.5.4 Orpharma Revenue in Rare Disease Pharmaceutical Service Business (2019-2024)
11.5.5 Orpharma Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Rare Disease Pharmaceutical Service Introduction
11.6.4 Amgen Revenue in Rare Disease Pharmaceutical Service Business (2019-2024)
11.6.5 Amgen Recent Development
11.7 Recordati
11.7.1 Recordati Company Detail
11.7.2 Recordati Business Overview
11.7.3 Recordati Rare Disease Pharmaceutical Service Introduction
11.7.4 Recordati Revenue in Rare Disease Pharmaceutical Service Business (2019-2024)
11.7.5 Recordati Recent Development
11.8 Novartis
11.8.1 Novartis Company Detail
11.8.2 Novartis Business Overview
11.8.3 Novartis Rare Disease Pharmaceutical Service Introduction
11.8.4 Novartis Revenue in Rare Disease Pharmaceutical Service Business (2019-2024)
11.8.5 Novartis Recent Development
11.9 Celgene
11.9.1 Celgene Company Detail
11.9.2 Celgene Business Overview
11.9.3 Celgene Rare Disease Pharmaceutical Service Introduction
11.9.4 Celgene Revenue in Rare Disease Pharmaceutical Service Business (2019-2024)
11.9.5 Celgene Recent Development
11.10 Amryt Pharma
11.10.1 Amryt Pharma Company Detail
11.10.2 Amryt Pharma Business Overview
11.10.3 Amryt Pharma Rare Disease Pharmaceutical Service Introduction
11.10.4 Amryt Pharma Revenue in Rare Disease Pharmaceutical Service Business (2019-2024)
11.10.5 Amryt Pharma Recent Development
11.11 Johnson & Johnson
11.11.1 Johnson & Johnson Company Detail
11.11.2 Johnson & Johnson Business Overview
11.11.3 Johnson & Johnson Rare Disease Pharmaceutical Service Introduction
11.11.4 Johnson & Johnson Revenue in Rare Disease Pharmaceutical Service Business (2019-2024)
11.11.5 Johnson & Johnson Recent Development
11.12 GSK
11.12.1 GSK Company Detail
11.12.2 GSK Business Overview
11.12.3 GSK Rare Disease Pharmaceutical Service Introduction
11.12.4 GSK Revenue in Rare Disease Pharmaceutical Service Business (2019-2024)
11.12.5 GSK Recent Development
11.13 Shire
11.13.1 Shire Company Detail
11.13.2 Shire Business Overview
11.13.3 Shire Rare Disease Pharmaceutical Service Introduction
11.13.4 Shire Revenue in Rare Disease Pharmaceutical Service Business (2019-2024)
11.13.5 Shire Recent Development
11.14 Merck
11.14.1 Merck Company Detail
11.14.2 Merck Business Overview
11.14.3 Merck Rare Disease Pharmaceutical Service Introduction
11.14.4 Merck Revenue in Rare Disease Pharmaceutical Service Business (2019-2024)
11.14.5 Merck Recent Development
11.15 Pfizer
11.15.1 Pfizer Company Detail
11.15.2 Pfizer Business Overview
11.15.3 Pfizer Rare Disease Pharmaceutical Service Introduction
11.15.4 Pfizer Revenue in Rare Disease Pharmaceutical Service Business (2019-2024)
11.15.5 Pfizer Recent Development
11.16 Biogen
11.16.1 Biogen Company Detail
11.16.2 Biogen Business Overview
11.16.3 Biogen Rare Disease Pharmaceutical Service Introduction
11.16.4 Biogen Revenue in Rare Disease Pharmaceutical Service Business (2019-2024)
11.16.5 Biogen Recent Development
11.17 Sanofi
11.17.1 Sanofi Company Detail
11.17.2 Sanofi Business Overview
11.17.3 Sanofi Rare Disease Pharmaceutical Service Introduction
11.17.4 Sanofi Revenue in Rare Disease Pharmaceutical Service Business (2019-2024)
11.17.5 Sanofi Recent Development
11.18 AstraZeneca
11.18.1 AstraZeneca Company Detail
11.18.2 AstraZeneca Business Overview
11.18.3 AstraZeneca Rare Disease Pharmaceutical Service Introduction
11.18.4 AstraZeneca Revenue in Rare Disease Pharmaceutical Service Business (2019-2024)
11.18.5 AstraZeneca Recent Development
11.19 Takeda
11.19.1 Takeda Company Detail
11.19.2 Takeda Business Overview
11.19.3 Takeda Rare Disease Pharmaceutical Service Introduction
11.19.4 Takeda Revenue in Rare Disease Pharmaceutical Service Business (2019-2024)
11.19.5 Takeda Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details